Drugs of Abuse Laboratory at King's College Hospital
Laboratory overview
Our Drugs of Abuse (DoA) Laboratory at Kings’ College Hospital provides an analytical service primarily to the Addictions Division of South London and Maudsley NHS Foundation Trust and local community centres to assess drug use or misuse, and to confirm adherence in inpatients undergoing rehabilitation for drug addiction.
Key features
- All samples sent for a ‘Standard’ Urine Drug Screen (UDS) are analysed using a combination of automated immunoassay, enzymatic assay, and liquid chromatography with high-resolution mass spectrometry (LC-HR-MS).
- Creatinine is measured as a marker of sample integrity on all urine samples. Individual drugs/metabolites and drug classes are reported as either ‘positive’ or ‘negative’ based on European Workplace Drug Testing Society ‘cut-off’ concentrations (www.ewdts.org).
- Additional specialist tests by enzymatic assay (urine ethanol), immunoassay (barbiturates), and by LC-HR-MS (buprenorphine and metabolites, ketamine and norketamine, mephedrone, tramadol and metabolites - see other analytes in the ‘Our Tests’ section of the website) are available on request, and can be carried out on the same specimen as supplied originally. Alternatively, a ‘Premium UDS’ test is available which includes a ‘Standard UDS’, plus the additional LC-HR-MS tests listed above.
Please check the Viapath website regularly for service updates – further new tests will be added in response to service requirements.
Toxicology Department at King's Hospital
Bessemer Wing - 3rd Floor
Denmark Hill
London SE5 9RS
Last updated: 02/11/2015
eMail alerts and news
Site details
Working with our NHS service partners to set the standard for the future of pathology


Viapath is a founding member of The Association of Independent Pathology Providers (AIPP), which is a trade association representing innovative research-based diagnostic testing companies.
Copyright 2014-2025 Synnovis Group LLP. Synnovis, the Synnovis logo and Nutris are registered trademarks of Synnovis Group LLP.